PTO/SB/08b (04-09)
Approved for use through 05/31/2009, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Application Number 10/580.962 INFORMATION DISCLOSURE Filing Date May 31, 2006 STATEMENT BY APPLICANT First Named Inventor Erik Buntinx Art Unit 4121 (Use as many sheets as necessary) Examiner Name Sarah Pihonak Attorney Docket Number 29248/29 1 of 1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	STEIN D J et al, entitled "Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders," J Clin Psychiatry, 1997, 58(3):119-122.	
	2	ALBERT U et al., entitled "Management of treatment resistant obsessive-compulsive disorder. Algorithms for Pharmacotherapy," Panminerva Med, 2002, 44(2):83-91.	
	3	Mohr N et al., entitled "Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorders," Int J Psychopharmacol, 2002, 17(1):37-40.	
	4	Silver H, entitled "Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia," 2003, Int Clin Psychopharmacol, 18(6):305-313.	
		*	

Examiner | /Sarah Pihonak/ | Date | Onsidered | O3/30/2010 | Considered | O3/30/2010 | Considered | O3/30/2010 | Considered | O3/30/2010 | Considered | Onsidered | Onsidered

considered, induced body of an experimental confidence of the property of the

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.